Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. Symmans · SciRah

Researcher profile · Semantic Scholar

W. Symmans

Share profile

W. Symmans — researcher profile on SciRah

h-index: 100
Works: 601
Citations: 46K

Most-cited papers

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.
Nadia Harbeck, S. Modi, L. Pusztai, S. Ohno +21 more
2025Annals of Oncology100 citations Open access
Semantic Scholar
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomised I-SPY2.2 phase 2 trial
R. Shatsky, M. Trivedi, C. Yau, Rita Nanda +56 more
2024Nature Medicine55 citations Open access
Semantic Scholar
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”
B. Lim, S. Seth, C. Yam, Lei Huo +27 more
2024Cell Reports Medicine26 citations Open access
Semantic Scholar
Datopotamab-deruxtecan in early stage breast cancer: the I-SPY2.2 sequential multiple assignment randomized phase 2 trial
Katia Khoury, J. Meisel, C. Yau, H. Rugo +53 more
2024Nature Medicine17 citations Open access
Semantic Scholar
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
M. Telli, J. Litton, J. T. Beck, Jason M Jones +13 more
2024Breast Cancer15 citations Open access
Semantic Scholar
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
R. Leon-Ferre, K. Dimitroff, C. Yau, K. Giridhar +12 more
2025Breast Cancer Research14 citations Open access
Semantic Scholar
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
Beverly Kyalwazi, C. Yau, Michael J. Campbell, T. Yoshimatsu +30 more
2023JAMA Network Open12 citations Open access
Semantic Scholar
Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
Otto Metzger, K. Ballman, J. Campbell, Minetta C. Liu +13 more
2025Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial
R. Mukhtar, K. Dimitroff, C. Yau, J. Chien +32 more
2025Annals of Surgical Oncology10 citations
Semantic Scholar
Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer
Reid T. Powell, Amanda L. Rinkenbaugh, Lei Guo, Shirong Cai +14 more
2024npj Breast Cancer10 citations Open access
Semantic Scholar
Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy
M. Magbanua, Ziad Ahmed, R. Sayaman, Lamorna Brown Swigart +14 more
2024Clinical Cancer Research9 citations Open access
Semantic Scholar
A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR)
V. Bossuyt, E. Provenzano, W. Symmans, F. Webster +14 more
2024Histopathology9 citations
Semantic Scholar
Abstract RF2-01: Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial
J. Boughey, V. Suman, K. J. Hunt, B. Haffty +10 more
2025Clinical Cancer Research8 citations
Semantic Scholar
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
H. Rugo, Mike Campbell, C. Yau, J. Chien +19 more
2024Breast Cancer Research and Treatment8 citations Open access
Semantic Scholar
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer
A. Grinshpun, D. Dustin, M. Cai, M. Hughes +11 more
2026ESMO Open6 citations Open access
Semantic Scholar
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
R. Mukhtar, Soumy Gottipati, C. Yau, S. López-Tarruella +42 more
2025npj Breast Cancer6 citations Open access
Semantic Scholar
ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.
Shu-Ying Liu, Hui-Qin Chen, M. Gagea, Lorenzo Federico +8 more
2025Cancer Letters6 citations Open access
Semantic Scholar
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502
D. Stover, R. Salgado, Oleksander Savenkov, K. Ballman +12 more
2024npj Breast Cancer6 citations Open access
Semantic Scholar
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
D. Wolf, C. Yau, M. Campbell, A. Glas +31 more
2025JCO Precision Oncology5 citations Open access
Semantic Scholar
Novel Postneoadjuvant Prognostic Breast Cancer Staging System.
David J. Winchester, L. Singh, Stephen B. Edge, Kimberly H. Allison +16 more
2025Journal of Clinical Oncology5 citations
Semantic Scholar
Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy
Akram Yazdani, H. Lenz, G. Pillonetto, Raul Mendez-Giraldez +19 more
2025Communications Medicine5 citations Open access
Semantic Scholar
Pre-analytical Best Practices for RNA Sequencing from Small Biopsies and Cytologic Specimens
G. Sura, K. B. Engel, S. Greytak, S. Gaston +9 more
2026Molecular Diagnosis & Therapy4 citations Open access
Semantic Scholar
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant Chemotherapy
Amanda L. Rinkenbaugh, Yuan Qi, Shirong Cai, Jiansu Shao +20 more
2025Cancer Research4 citations
Semantic Scholar
Stain SAN: simultaneous augmentation and normalization for histopathology images
Taebin Kim, Yao Li, B. Calhoun, A. Thennavan +5 more
2024Journal of Medical Imaging4 citations Open access
Semantic Scholar
Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial
J. Tseng, K. Dimitroff, C. Sauder, A. Chien +39 more
2026Annals of Surgical Oncology3 citations Open access
Semantic Scholar
Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
S. Alkhafaji, M. Magbanua, L. J. van 't Veer, K. Giridhar +16 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial
J. van Hassel, K. Dimitroff, C. Yau, R. Mukhtar +29 more
2025Annals of Surgical Oncology3 citations Open access
Semantic Scholar
Adjuvant Platinum versus Capecitabine for Residual Invasive Triple-Negative Breast Cancer: Patient-Reported Outcomes in ECOG-ACRIN EA1131
Karen L. Smith, Feng-Min Zhao, I. Mayer, Amye J. Tevaarwerk +21 more
2024Cancer3 citations
Semantic Scholar
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer
F. Howard, J. Dolezal, Hanna M. Hieromnimon, S. Venters +32 more
2025medRxiv2 citations Open access
Semantic Scholar
EMT-induced stem cell and mesenchymal programs can be decoupled via cell division and ESRP1-dependent mechanisms
P. den Hollander, M. Castañeda, S. Vasaikar, Joanna Joyce Maddela +18 more
2025iScience2 citations Open access
Semantic Scholar
Abstract GS03-07: Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer
D. Stover, D. Hlauschek, E. Mayer, W. Symmans +20 more
2024Cancer Research2 citations
Semantic Scholar
Comparative analysis of Ficoll-Hypaque and CytoLyt techniques for blood removal in breast cancer malignant effusions: effects on RNA quality and sequencing outcomes
G. Sura, K. Tran, Alexander J. Trevarton, M. Marczyk +11 more
2024Journal of the American Society of Cytopathology2 citations Open access
Semantic Scholar
The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer
S. Seth, C. Yam, L. Huo, B. Lim +26 more
2026Breast Cancer Research1 citations Open access
Semantic Scholar
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence
N. Nguyen, An-Ran Li, S. Kochanny, J. Dolezal +29 more
2026medRxiv1 citations Open access
Semantic Scholar
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer
F. Howard, An-Ran Li, S. Kochanny, M. Sullivan +21 more
2026medRxiv1 citations Open access
Semantic Scholar
Abstract RF3-04: Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial
H. A. Parsons, K. Ballman, E. Heitzer, M. Watson +25 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Miguel Martín, Á. Rodríguez-Lescure, C. Reboredo, Eveline Chen +22 more
2026Clinical Cancer Research1 citations Open access
Semantic Scholar
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial
Moriah Forster, Feng-Min Zhao, Sarah Bell, I. Mayer +25 more
2026JCO oncology advances1 citations Open access
Semantic Scholar
Abstract GS3-05: Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial
E. Mamounas, H. Bandos, K. J. Sweeney, K. Tran +15 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Abstract PS3-07-10: Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot
K. Giridhar, M. Goetz, C. Yau, A. Wallace +27 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Abstract PS4-01: Predictor of benefit from dose-dense paclitaxel chemotherapy for patients with hormone receptor-positive HER2-negative breast cancer. A GEICAM/9906 sub-study
Miguel Martín, Á. Rodríguez-Lescure, L. Calvo, Eveline Chen +21 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial.
F. Penault-Llorca, A. Lusque, T. Filleron, K. Tran +9 more
2025European Journal of Cancer1 citations Open access
Semantic Scholar
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial
M. Kaur, K. Dimitroff, J. Boughey, L. Esserman +35 more
2025Annals of Surgical Oncology1 citations
Semantic Scholar
Prospective and retrospective analysis of whole slide images of sentinel and targeted lymph node frozen sections in breast cancer.
Qiqi Ye, Timothy Law, Dianna Klippel, Constance T. Albarracin +13 more
2025Modern Pathology1 citations
Semantic Scholar
Abstract PS09-03: Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer
V. Valero, J. Mouabbi, Heather Alonzo, P. Pohlmann +12 more
2024Cancer Research1 citations
Semantic Scholar
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
R. Leon-Ferre, K. Dimitroff, C. Yau, K. Giridhar +7 more
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Abstract 6620: PDX models of TNBC established from pre- and post-therapy tumors identify vulnerabilities of resistant disease
Amanda L. Rinkenbaugh, Yuan Qi, Reid T. Powell, Shirong Cai +15 more
2024Cancer Research1 citations
Semantic Scholar
An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapy
Amanda L. Rinkenbaugh, Yuan Qi, Shirong Cai, Jiansu Shao +20 more
2024bioRxiv1 citations Open access
Semantic Scholar
2026 RISE UP for Breast Cancer and Women’s Health Conference
Vicky Ro, Christina Hijiya, Alissa Michel, Cynthia Law +148 more
2026Breast Cancer Research and Treatment0 citations Open access
Semantic Scholar
AI-derived tumor-infiltrating lymphocytes enhance the prediction of pathologic complete response in early-stage triple-negative breast cancer
Xiao-Xiao Pan, Caner Ercan, Zhong-Ya Wang, Roland L. Bassett +18 more
2026npj Breast Cancer0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Yau×15
Invite
C. Yau — researcher profile on SciRah
A. DeMichele×15
Invite
A. DeMichele — researcher profile on SciRah
L. J. van 't Veer×12
Invite
L. J. van 't Veer — researcher profile on SciRah
J. Perlmutter×11
Invite
J. Perlmutter — researcher profile on SciRah

×10

Invite

H. Rugo — researcher profile on SciRah

Invite

G. Hirst — researcher profile on SciRah

Invite

L. Esserman — researcher profile on SciRah

Invite

A. Wallace — researcher profile on SciRah

Invite

J. Boughey — researcher profile on SciRah

Invite

C. Isaacs — researcher profile on SciRah

Invite

L. Pusztai — researcher profile on SciRah

Invite

R. Shatsky — researcher profile on SciRah